-
Mashup Score: 0#ESMO20 Education Weekend regional talks: Latin America - 3 year(s) ago
This latest edition from our #ESMO20 Education Weekend Regional Talk series focused on highlights from the Latin American perspective. We asked panellists fr…
Source: YouTubeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 13Sacituzumab Shines in ASCENT TNBC Trial - 3 year(s) ago
The novel antibody–drug conjugate sacituzumab govitecan-hziy has provided an overall survival benefit over conventional chemotherapy for patients with advanced triple-negative breast cancer, according to results of the multicenter phase 3 ASCENT trial. A biomarker analysis of the data shows clinical benefit with was found regardless of level of trophoblast cell-surface antigen-2 expression.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sacituzumab provided an overall survival benefit over conventional chemotherapy for patients with advanced TNBC. https://t.co/Dwfy6hoFvG @ABhealer108 @DrWGradishar #sacituzumab #breastcancer #ESMO20 #SABCS20
-
-
Mashup Score: 16Log In or Sign Up to View - 3 year(s) ago
See posts, photos and more on Facebook.
Source: www.facebook.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us for a South American delve into regional highlights from the #ESMO20 Education Weekend, & how this translates into daily practice. Facebook - 18/4 19:00 CEST w/ @E_de_Azambuja, @Betzabe100, @Martin_AngelMD, @AndreaAnampaG, @demattosarruda 👉https://t.co/mdZ1KNHEVU https://t.co/3hm4Xvf0HZ
-
-
Mashup Score: 7Sacituzumab Shines in ASCENT TNBC Trial - 3 year(s) ago
The novel antibody–drug conjugate sacituzumab govitecan-hziy has provided an overall survival benefit over conventional chemotherapy for patients with advanced triple-negative breast cancer, according to results of the multicenter phase 3 ASCENT trial. A biomarker analysis of the data shows clinical benefit with was found regardless of level of trophoblast cell-surface antigen-2 expression.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sacituzumab provided an overall survival benefit over conventional chemotherapy for patients with advanced TNBC. https://t.co/Dwfy6hGgUg @ABhealer108 @DrWGradishar #sacituzumab #breastcancer #ESMO20 #SABCS20
-
-
Mashup Score: 2
Treatment for advanced kidney cancer has undergone an impressive improvement in recent years due to the development of targeted therapies against VEGF, a key driver of angiogenesis, or mTOR pathways and immunotherapy.
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from #ESMO20 & #GU21 highlight progress in #KidneyCancer treatment https://t.co/8kiQUy4Y4L #ASCODailyNews @T_AlonsoGordoa @JaviMolinaC @Javi_poz @AlfredoCarrato #GUCSM
-
-
Mashup Score: 0
The impact of clinicopathologic factors, cancer type, stage or therapies on outcomes of pts with COVID19 is not well defined. We systematically and comprehensively identified and assessed factors associated with high mortality (M) in the largest cohort of pts with cancer and COVID-19.
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Clinical & lab prognostic fx in Pts w/ cancer & SARS-CoV-2: #COVID19 & Cancer Consortium (#CCC19) [Sep 1, 2020] @PGrivasMDPhD et al. @COVID19nCCC https://t.co/h0MzpqFM66 LBA172 #ESMO20 ABnl ALC, high ANC, low Plt, ABnl Crt, d-dimer, troponin & CRP assoc worse 30d mortality https://t.co/bK2L1pIhIU
-
-
Mashup Score: 0LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis - 3 year(s) ago
SARS-CoV-2 is associated with diverse clinical presentations ranging from asymptomatic infection to lethal complications. Small studies have suggested inferior outcomes in patients (pts) on active cancer treatment. This finding was not independently validated in our prior report on 928 pts, which included treatments administered within 4 weeks of COVID-19 diagnosis. Here, we examine outcomes…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A #CCC19 registry analysis [Sep 1, 2020] @TMWiseDraper et al. @COVID19nCCC LBA171 #ESMO20 https://t.co/aGgeh244g5 #COVID19nCancer #COVID19 https://t.co/O4wfB3fYEP
-
-
Mashup Score: 0LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis - 3 year(s) ago
SARS-CoV-2 is associated with diverse clinical presentations ranging from asymptomatic infection to lethal complications. Small studies have suggested inferior outcomes in patients (pts) on active cancer treatment. This finding was not independently validated in our prior report on 928 pts, which included treatments administered within 4 weeks of COVID-19 diagnosis. Here, we examine outcomes…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A #CCC19 registry analysis [Sep 1, 2020] @TMWiseDraper et al. @COVID19nCCC LBA171 #ESMO20 https://t.co/aGgeh244g5 #COVID19nCancer #COVID19 https://t.co/al6FyavejA
-
-
Mashup Score: 0
The impact of clinicopathologic factors, cancer type, stage or therapies on outcomes of pts with COVID19 is not well defined. We systematically and comprehensively identified and assessed factors associated with high mortality (M) in the largest cohort of pts with cancer and COVID-19.
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Clinical & lab prognostic fx in Pts w/ cancer & SARS-CoV-2: #COVID19 & Cancer Consortium (#CCC19) [Sep 1, 2020] @PGrivasMDPhD et al. @COVID19nCCC https://t.co/h0MzpqFM66 LBA172 #ESMO20 ABnl ALC, high ANC, low Plt, ABnl Crt, d-dimer, troponin & CRP assoc worse 30d mortality https://t.co/1dBhAqYBoQ
-
-
Mashup Score: 1LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis - 3 year(s) ago
SARS-CoV-2 is associated with diverse clinical presentations ranging from asymptomatic infection to lethal complications. Small studies have suggested inferior outcomes in patients (pts) on active cancer treatment. This finding was not independently validated in our prior report on 928 pts, which included treatments administered within 4 weeks of COVID-19 diagnosis. Here, we examine outcomes…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A #CCC19 registry analysis [Sep 1, 2020] @TMWiseDraper et al. @COVID19nCCC LBA171 #ESMO20 https://t.co/aGgeh244g5 #COVID19nCancer #COVID19 https://t.co/2kR07YAw0Z
-
Many thanks again to the great panellists from our #LatinAmerica talk on highlights from the #ESMO20 Education Weekend - now on-demand here: https://t.co/4P7mxCMWtH Don't forget, #ESMO20 resources are available to ESMO members & event delegates here👉 https://t.co/OzyjR4MPnO https://t.co/12fCM7r5NT